Langsat (Lansium domesticum) is a plant that thrives in the tropics. The search for photoprotective compounds derived from natural ingredients has been intensively conducted to develop cosmetic formulations to obtain safe and protective products against UV rays. This study aims to identify chemical compounds in the ethyl acetate fraction and residues of ethanol extract from L. domesticum bark using tube and gas chromatography-mass spectrophotometry tests. At the same time, the antioxidant activity and SPF values were assessed with the DPPH and FRAP methods. The qualitative GC-MS test obtained the percentage peak value and molecular weight. Furthermore, the antioxidant activity was tested using the compound DPPH measured with an ELISA reader at a wavelength of 515.5 nm with UV/vis spectrophotometer and FRAP method using FeCl3 and TPTZ compounds at 615 nm. The SPF value was assessed using Mansur's formula with UV/Vis spectrophotometer at 290 to 320 nm. The results obtained in the ethyl acetate fraction showed terpenoids, while the residue contains phenolics, flavonoids, tannins, and saponins. The GC-MS tests found that the ethyl acetate fraction had 47 types of chemical compounds, including terpenoids and fatty acids group; in the residue, four classes were found, with terpenoid and fatty acid groups being more predominant. Based on the results, the ethyl acetate fraction has an IC50 value of 341.25±26.45 µg/ml and 436.3±10.8 µg/ml; the residue was 94.72±34.22 µg/ml and 2602.79±11.8 µg/ml. Additionally, the SPF values for both were 2.87 and 3.9.
{"title":"Chemical Screening and Antioxidant Activity of Ethyl Acetate Fraction and Residue from Lansium domesticum Ethanolic Extract","authors":"P. Apridamayanti, R. Sari","doi":"10.33084/bjop.v6i1.3867","DOIUrl":"https://doi.org/10.33084/bjop.v6i1.3867","url":null,"abstract":"Langsat (Lansium domesticum) is a plant that thrives in the tropics. The search for photoprotective compounds derived from natural ingredients has been intensively conducted to develop cosmetic formulations to obtain safe and protective products against UV rays. This study aims to identify chemical compounds in the ethyl acetate fraction and residues of ethanol extract from L. domesticum bark using tube and gas chromatography-mass spectrophotometry tests. At the same time, the antioxidant activity and SPF values were assessed with the DPPH and FRAP methods. The qualitative GC-MS test obtained the percentage peak value and molecular weight. Furthermore, the antioxidant activity was tested using the compound DPPH measured with an ELISA reader at a wavelength of 515.5 nm with UV/vis spectrophotometer and FRAP method using FeCl3 and TPTZ compounds at 615 nm. The SPF value was assessed using Mansur's formula with UV/Vis spectrophotometer at 290 to 320 nm. The results obtained in the ethyl acetate fraction showed terpenoids, while the residue contains phenolics, flavonoids, tannins, and saponins. The GC-MS tests found that the ethyl acetate fraction had 47 types of chemical compounds, including terpenoids and fatty acids group; in the residue, four classes were found, with terpenoid and fatty acid groups being more predominant. Based on the results, the ethyl acetate fraction has an IC50 value of 341.25±26.45 µg/ml and 436.3±10.8 µg/ml; the residue was 94.72±34.22 µg/ml and 2602.79±11.8 µg/ml. Additionally, the SPF values for both were 2.87 and 3.9.","PeriodicalId":9118,"journal":{"name":"Borneo Journal of Pharmacy","volume":"39 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81067323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Assalamu’alaikum Wr. Wb. Alhamdulillahirabbil ‘alamin. The next edition of Borneo Journal of Pharmacy (Borneo J Pharm), has been published in February 2023. This edition contains ten articles: Pharmacology-Toxicology, Pharmacognosy-Phytochemistry, Pharmaceutical, Analytical Pharmacy-Medicinal Chemistry, Clinical-Community Pharmacy, and Management Pharmacy. This edition includes writings from six countries: Anguilla, Costa Rica, India, Indonesia, Nigeria, and Russian Federation. The authors come from several institutions, including Universitas Islam Indonesia, Sekolah Tinggi Ilmu Farmasi Riau, Universitas Andalas, Pyatigorsk Medical and Pharmaceutical Institute, Universitas Muhammadiyah Banjarmasin, Universitas Tanjungpura, Universidad de Costa Rica, Ahmadu Bello University, Akademi Farmasi Surabaya, Universitas Airlangga, Universitas Sumatera Utara, Sekolah Tinggi Ilmu Kesehatan Senior Medan, Prathima Institute of Medical Sciences, Saint James School of Medicine, Vaagdevi Degree and PG College, and Vydehi Institute of Medical Science and Research Center. Editorial boards are fully aware that there are still room for improvement in this edition, hence with all humility willing to accept constructive suggestions and feedback for improvements to the publication for the next editions. The editorial board would like to thank all editors and reviewers, and contributors of the scientific articles who have provided the repetoire in this issue. We hope that all parties, especially the contributors, could re-participate for the publication in the next edition on May 2023. Wassalamu’alaikum Wr. Wb.
{"title":"Cover, Content, and Editorial Note from Borneo J Pharm Vol. 6 No. 1 February 2023","authors":"C. E. O. Borneo J Pharm","doi":"10.33084/bjop.v6i1.5077","DOIUrl":"https://doi.org/10.33084/bjop.v6i1.5077","url":null,"abstract":"Assalamu’alaikum Wr. Wb. \u0000Alhamdulillahirabbil ‘alamin. The next edition of Borneo Journal of Pharmacy (Borneo J Pharm), has been published in February 2023. This edition contains ten articles: Pharmacology-Toxicology, Pharmacognosy-Phytochemistry, Pharmaceutical, Analytical Pharmacy-Medicinal Chemistry, Clinical-Community Pharmacy, and Management Pharmacy. This edition includes writings from six countries: Anguilla, Costa Rica, India, Indonesia, Nigeria, and Russian Federation. The authors come from several institutions, including Universitas Islam Indonesia, Sekolah Tinggi Ilmu Farmasi Riau, Universitas Andalas, Pyatigorsk Medical and Pharmaceutical Institute, Universitas Muhammadiyah Banjarmasin, Universitas Tanjungpura, Universidad de Costa Rica, Ahmadu Bello University, Akademi Farmasi Surabaya, Universitas Airlangga, Universitas Sumatera Utara, Sekolah Tinggi Ilmu Kesehatan Senior Medan, Prathima Institute of Medical Sciences, Saint James School of Medicine, Vaagdevi Degree and PG College, and Vydehi Institute of Medical Science and Research Center. \u0000Editorial boards are fully aware that there are still room for improvement in this edition, hence with all humility willing to accept constructive suggestions and feedback for improvements to the publication for the next editions. The editorial board would like to thank all editors and reviewers, and contributors of the scientific articles who have provided the repetoire in this issue. We hope that all parties, especially the contributors, could re-participate for the publication in the next edition on May 2023. \u0000Wassalamu’alaikum Wr. Wb.","PeriodicalId":9118,"journal":{"name":"Borneo Journal of Pharmacy","volume":"56 1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77396880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Selly Septi Fandinata, Rizky Darmawan, N. M. Ulfa, Deddy Aryanda Putra
Hypertension crisis is one of the most common disease problems; it will cause complications and death. Therapeutic management guidelines that the calcium channel blocker group, one of which is nicardipine, can increase the achievement of goals in mean arterial pressure (MAP) in preventing the progression of organ damage. This study aimed to evaluate the use of nicardipine therapy on the MAP and blood pressure (BP) in patients with hypertension crisis. The research design was cross-sectional with statistical analysis—retrospective data collection at Hajj General Hospital Surabaya for August to December 2021. The number of samples in this study matched the inclusion criteria; 20 patients were obtained, 16 with a diagnosis of hypertension emergency, and four with hypertension urgency who received single or combined intravenous nicardipine therapy <0.005 with an average BP decrease of pre 20.375±31.492/103.50±10.400 mmHg and post 121.34±14.364/81.80±11.186 so that intravenous nicardipine therapy was significant in reducing systolic and diastolic BP. In the profile of the MAP value statistically using the paired T-test, it was found that the P-value was 0.000 < 0.005 with a decrease in the MAP pre-value of 135.028±13.8857 mmHg and post 93.650±8.9499 mmHg, showing a reduction in MAP as expected. In conclusion, using nicardipine intravenously at a 5 mg/hour dose has shown an optimal decrease in BP and MAP in hypertensive emergency and urgency patients.
{"title":"Changes in Mean Arterial and Blood Pressure in Using Nicardipine in Hypertensive Crisis Patients at the Hajj General Hospital Surabaya from August to December 2021","authors":"Selly Septi Fandinata, Rizky Darmawan, N. M. Ulfa, Deddy Aryanda Putra","doi":"10.33084/bjop.v6i1.3493","DOIUrl":"https://doi.org/10.33084/bjop.v6i1.3493","url":null,"abstract":"Hypertension crisis is one of the most common disease problems; it will cause complications and death. Therapeutic management guidelines that the calcium channel blocker group, one of which is nicardipine, can increase the achievement of goals in mean arterial pressure (MAP) in preventing the progression of organ damage. This study aimed to evaluate the use of nicardipine therapy on the MAP and blood pressure (BP) in patients with hypertension crisis. The research design was cross-sectional with statistical analysis—retrospective data collection at Hajj General Hospital Surabaya for August to December 2021. The number of samples in this study matched the inclusion criteria; 20 patients were obtained, 16 with a diagnosis of hypertension emergency, and four with hypertension urgency who received single or combined intravenous nicardipine therapy <0.005 with an average BP decrease of pre 20.375±31.492/103.50±10.400 mmHg and post 121.34±14.364/81.80±11.186 so that intravenous nicardipine therapy was significant in reducing systolic and diastolic BP. In the profile of the MAP value statistically using the paired T-test, it was found that the P-value was 0.000 < 0.005 with a decrease in the MAP pre-value of 135.028±13.8857 mmHg and post 93.650±8.9499 mmHg, showing a reduction in MAP as expected. In conclusion, using nicardipine intravenously at a 5 mg/hour dose has shown an optimal decrease in BP and MAP in hypertensive emergency and urgency patients.","PeriodicalId":9118,"journal":{"name":"Borneo Journal of Pharmacy","volume":"16 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87582131","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ariana Araya, David Arias, Karla Coto, María Rebeca López, Joselyn Rivera, Juan José Mora
Antisense oligonucleotides are drugs whose mechanism is based on binding to RNA target sequences. For this purpose, they modify the protein expression through steric hindrance and exon omission. Its production involves several steps: synthesis, purification, and lyophilization. Usually, the most complicated procedure is synthesis due to the chemical reactions necessary to add the required oligonucleotide bases. BP1001, inotersen, nusinersen, eteplirsen, and golodirsen are a few antisense drugs developed for treating neurodegenerative and neuromuscular diseases. Although antisense oligonucleotides present off-target reactions, multiple studies are being performed. The following review shows information regarding the pharmaceutical characteristics for industrial production and the current state of applicability in clinical practice. In conclusion, some molecules have already been approved for commercialization (inotersen, nusinersen, ataluren, eteplirsen, and golodirsen), showing them as promising therapeutic solutions in the short and medium term for disorders developed by specific genetic factors.
{"title":"Antisense Oligonucleotides: Concepts and Pharmaceutical Applications","authors":"Ariana Araya, David Arias, Karla Coto, María Rebeca López, Joselyn Rivera, Juan José Mora","doi":"10.33084/bjop.v6i1.2092","DOIUrl":"https://doi.org/10.33084/bjop.v6i1.2092","url":null,"abstract":"Antisense oligonucleotides are drugs whose mechanism is based on binding to RNA target sequences. For this purpose, they modify the protein expression through steric hindrance and exon omission. Its production involves several steps: synthesis, purification, and lyophilization. Usually, the most complicated procedure is synthesis due to the chemical reactions necessary to add the required oligonucleotide bases. BP1001, inotersen, nusinersen, eteplirsen, and golodirsen are a few antisense drugs developed for treating neurodegenerative and neuromuscular diseases. Although antisense oligonucleotides present off-target reactions, multiple studies are being performed. The following review shows information regarding the pharmaceutical characteristics for industrial production and the current state of applicability in clinical practice. In conclusion, some molecules have already been approved for commercialization (inotersen, nusinersen, ataluren, eteplirsen, and golodirsen), showing them as promising therapeutic solutions in the short and medium term for disorders developed by specific genetic factors.","PeriodicalId":9118,"journal":{"name":"Borneo Journal of Pharmacy","volume":"22 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82499043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Mutiara Siahaan, A. Nasution, W. Wiryanto, I. Iksen
Patients with hypertension usually experience chronic comorbidities and complications that require complex treatment (polypharmacy), which can further cause drug-related problems (DRPs) and interfere with the required clinical outcomes. This study, by using a case-control prospective cross-sectional, aimed to analyze the association between DRPs and blood pressures (BPs) of hypertensive patients admitted to Universitas Sumatera Utara (USU) hospital from July to September 2021. The incidence of DRPs was analyzed and classified according to the Cipolle classification system and reliable literature. Blood pressures of the patients were classified into controlled and uncontrolled BPs. The association between DRPs and BP was analyzed using the Chi-Square test. Most of the patients (57.5%) were female. Their mean age was 59±9.94 (years). The mean incidence of DRPs experienced by the patients was 1.78±0.79. The most frequently occurred DRPs were drug interactions. There was a significant association between the number of DRPs experienced by the patients and their BPs (p=0.02). DRPs are the contributing factor to the uncontrolled BPs of hypertensive patients.
高血压患者通常会出现慢性合并症和并发症，需要复杂的治疗(多种药物)，这可能进一步导致药物相关问题(DRPs)并干扰所需的临床结果。本研究采用病例对照前瞻性横断面法，旨在分析2021年7月至9月入住Universitas sumata Utara (USU)医院的高血压患者DRPs与血压(bp)之间的关系。根据Cipolle分类系统和可靠文献对DRPs的发生率进行分析和分类。将患者的血压分为控制血压和不控制血压。采用卡方检验分析DRPs与BP之间的相关性。绝大多数患者为女性(57.5%)。平均年龄59±9.94岁。患者DRPs的平均发生率为1.78±0.79。最常见的drp是药物相互作用。患者经历的drp次数与其bp之间存在显著相关性(p=0.02)。DRPs是导致高血压患者血压失控的重要因素。
{"title":"Association between Drug-Related Problems and Blood Pressure of Hypertensive Patients Admitted to Universitas Sumatera Utara Hospital","authors":"Mutiara Siahaan, A. Nasution, W. Wiryanto, I. Iksen","doi":"10.33084/bjop.v6i1.3664","DOIUrl":"https://doi.org/10.33084/bjop.v6i1.3664","url":null,"abstract":"Patients with hypertension usually experience chronic comorbidities and complications that require complex treatment (polypharmacy), which can further cause drug-related problems (DRPs) and interfere with the required clinical outcomes. This study, by using a case-control prospective cross-sectional, aimed to analyze the association between DRPs and blood pressures (BPs) of hypertensive patients admitted to Universitas Sumatera Utara (USU) hospital from July to September 2021. The incidence of DRPs was analyzed and classified according to the Cipolle classification system and reliable literature. Blood pressures of the patients were classified into controlled and uncontrolled BPs. The association between DRPs and BP was analyzed using the Chi-Square test. Most of the patients (57.5%) were female. Their mean age was 59±9.94 (years). The mean incidence of DRPs experienced by the patients was 1.78±0.79. The most frequently occurred DRPs were drug interactions. There was a significant association between the number of DRPs experienced by the patients and their BPs (p=0.02). DRPs are the contributing factor to the uncontrolled BPs of hypertensive patients.","PeriodicalId":9118,"journal":{"name":"Borneo Journal of Pharmacy","volume":"27 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77876759","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
V. Kandi, Sabitha Vadakedath, Purna Singh Addanki, Vikram Godishala, V. Pinnelli
The research carried out to find a better treatment, improve healthcare, and benefit the current medical practice is termed clinical research. Clinical trial includes the pharmacodynamics (mechanisms of action of a new drug), pharmacokinetics (drug metabolism inside the body), therapeutics (efficacy of the drug), and adverse effects (safety of the drug) of the novel medical products. Clinical research is a process that involves human subjects and their biological specimens. The clinical trial is a meticulously planned protocol-based study of a drug/device to discover a new/better way to prevent, diagnose, and treat a disease/illness. Considering the involvement of both healthy and diseased people in clinical trials, the regulatory authorities have a significant role in the processes involving the conduction of clinical research and carefully evaluate their potential implications on humans. Because clinical trials are usually aimed at assessing the safety and efficacy of novel pharmaceutical compounds and medical devices, pharmacovigilance laws and risk management assume increased significance while conducting clinical research/trials. In this review, we attempt to discuss the regulatory authorities' roles in different geographical regions, including the United States of America, The European Union, and India. We also focus on the importance of pharmacovigilance laws and risk management during clinical trials.
{"title":"Clinical Trials: The Role of Regulatory Agencies, Pharmacovigilance Laws, Guidelines, Risk Management, Patenting, and Publicizing Results","authors":"V. Kandi, Sabitha Vadakedath, Purna Singh Addanki, Vikram Godishala, V. Pinnelli","doi":"10.33084/bjop.v6i1.3263","DOIUrl":"https://doi.org/10.33084/bjop.v6i1.3263","url":null,"abstract":"The research carried out to find a better treatment, improve healthcare, and benefit the current medical practice is termed clinical research. Clinical trial includes the pharmacodynamics (mechanisms of action of a new drug), pharmacokinetics (drug metabolism inside the body), therapeutics (efficacy of the drug), and adverse effects (safety of the drug) of the novel medical products. Clinical research is a process that involves human subjects and their biological specimens. The clinical trial is a meticulously planned protocol-based study of a drug/device to discover a new/better way to prevent, diagnose, and treat a disease/illness. Considering the involvement of both healthy and diseased people in clinical trials, the regulatory authorities have a significant role in the processes involving the conduction of clinical research and carefully evaluate their potential implications on humans. Because clinical trials are usually aimed at assessing the safety and efficacy of novel pharmaceutical compounds and medical devices, pharmacovigilance laws and risk management assume increased significance while conducting clinical research/trials. In this review, we attempt to discuss the regulatory authorities' roles in different geographical regions, including the United States of America, The European Union, and India. We also focus on the importance of pharmacovigilance laws and risk management during clinical trials.","PeriodicalId":9118,"journal":{"name":"Borneo Journal of Pharmacy","volume":"18 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81025740","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Adriani Susanty, Mira Febrina, Dian Sanita Putri, Ihsan Ikhtiarudin, F. Wahyuni, Dachriyanus Dachriyanus
The cytotoxicity of ethyl acetate extract from Tampa badak (Voacanga foetida (Bl.) Rolfe) leaves against Artemia salina leach larvae was determined using the brine shrimp lethality test (BSLT) method and was evaluated against T47D breast cancer cells using MTT assay method. The result of BSLT showed a consistent result with MTT assay, which is the result obtained that ethyl acetate extract is very toxic against A. salina Leach larvae with LC50 value of 8.61 µg/mL and very cytotoxic against T47D breast cancer cells with IC50 values of 0.87; 0.66; and 0.95 µg/mL at the 24, 48 and 72 hours of incubation times, respectively. The MTT assay data were analyzed using a two-way ANOVA statistical method to see the effect of the dependent variable (concentration and time) on the independent variable (% viability). Based on the statistical test result, there is a difference in % viability between concentrations of 0.1; 1; and 10 µg/mL (p <0.05), but the length of incubation does not affect % viability (p >0.05).
{"title":"Cytotoxic Activity of Ethyl Acetate Extract from Voacanga foetida (Bl.) Rolfe Leaves Against T47D Breast Cancer Cells","authors":"Adriani Susanty, Mira Febrina, Dian Sanita Putri, Ihsan Ikhtiarudin, F. Wahyuni, Dachriyanus Dachriyanus","doi":"10.33084/bjop.v6i1.3499","DOIUrl":"https://doi.org/10.33084/bjop.v6i1.3499","url":null,"abstract":"The cytotoxicity of ethyl acetate extract from Tampa badak (Voacanga foetida (Bl.) Rolfe) leaves against Artemia salina leach larvae was determined using the brine shrimp lethality test (BSLT) method and was evaluated against T47D breast cancer cells using MTT assay method. The result of BSLT showed a consistent result with MTT assay, which is the result obtained that ethyl acetate extract is very toxic against A. salina Leach larvae with LC50 value of 8.61 µg/mL and very cytotoxic against T47D breast cancer cells with IC50 values of 0.87; 0.66; and 0.95 µg/mL at the 24, 48 and 72 hours of incubation times, respectively. The MTT assay data were analyzed using a two-way ANOVA statistical method to see the effect of the dependent variable (concentration and time) on the independent variable (% viability). Based on the statistical test result, there is a difference in % viability between concentrations of 0.1; 1; and 10 µg/mL (p <0.05), but the length of incubation does not affect % viability (p >0.05).","PeriodicalId":9118,"journal":{"name":"Borneo Journal of Pharmacy","volume":"1176 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77104531","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cynthia Astiti Putri, Farida Hayati, L. Chabib, Muhammad Iqbal Pangestu
Ipomoea reptans Poir has many health benefits, such as decreasing blood glucose and as an antioxidant. Self-nano emulsifying drug delivery systems (SNEDDS) are an innovation in pharmaceutical technology that minimizes drug molecules and maximizes surface area, thus increasing drug absorption. This study aimed to investigate SNEDDS of I. reptans acute toxicity in female Wistar rats. An acute toxicity test was done using a limit test of OECD 423. Female Wistar rats were divided into control and treatment groups, with three animals for each group being used per step. No animals died after they were given SNEDDS of I. reptans leaves extract at a dose of 2000 mg/kg. No toxic effect was detected at clinical examination and histopathology of the organ. SNEDDS of I. reptans leaves extract had an LD50 cut-off value of 5000 mg/kg.
{"title":"Acute Toxicity of Self-Nanoemulsifying Drug Delivery System of Ipomoea reptans Poir Leaves Extract on Female Wistar Rats","authors":"Cynthia Astiti Putri, Farida Hayati, L. Chabib, Muhammad Iqbal Pangestu","doi":"10.33084/bjop.v6i1.2099","DOIUrl":"https://doi.org/10.33084/bjop.v6i1.2099","url":null,"abstract":"Ipomoea reptans Poir has many health benefits, such as decreasing blood glucose and as an antioxidant. Self-nano emulsifying drug delivery systems (SNEDDS) are an innovation in pharmaceutical technology that minimizes drug molecules and maximizes surface area, thus increasing drug absorption. This study aimed to investigate SNEDDS of I. reptans acute toxicity in female Wistar rats. An acute toxicity test was done using a limit test of OECD 423. Female Wistar rats were divided into control and treatment groups, with three animals for each group being used per step. No animals died after they were given SNEDDS of I. reptans leaves extract at a dose of 2000 mg/kg. No toxic effect was detected at clinical examination and histopathology of the organ. SNEDDS of I. reptans leaves extract had an LD50 cut-off value of 5000 mg/kg.","PeriodicalId":9118,"journal":{"name":"Borneo Journal of Pharmacy","volume":"24 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81500408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Tidur merupakan suatu kegiatan normal yang akan dialami setiap individu dan menjadi aktivitas manusiawi namun banyak mahasiswa yang tidak memedulikan kualitas tidur yang baik, sehingga mempengaruhi tingkat kebugaran dan akan akan berdampak buruk bagi tubuh. Oleh karena itu, dengan memberikan senam yoga diharapkan menjadi salah satu cara dalam meningkatkan kualitas tidur pada berbagai umur dan penderita ganguan kualitas tidur. Tujuan penelitian ini untuk identifikasi efektifitas yoga terhadap peningkatan kualitas tidur pada mahasiswa. Metode penelitian ini menggunakan desain quasi experimental without control groub yang diberikan pre-test dan post-test. Populasi dalam penelitian adalah semua mahasiswa Prodi keperawatan Politeknik Kaltara dengan jumlah populasi 131 populasi dengan teknik pengambilan sampel menggunakan purposive sampling pada mahasiswa keperawatan tingkat 1 dengan jumlah sampel 33 sampel. Tahapan penelitian terdiri dari 3 tahapan. Analisa data yang digunakan adalah analisis univariat dan bivariat. Hasil uji analisis menggunakan McNemar dan didapatkan ρ-value = 0.000 (< 0,05) yang berarti terdapat perbedaan signifikan terhadap kualitas tidur sebelum dan sesudah intervensi senam yoga. Kesimpulan dari penelitian ini adalah senam yoga dapat meningkatkan kualitas tidur pada mahasiswa Keperawatan di Politeknik Kaltara.
{"title":"Pengaruh yoga terhadap peningkatan kualitas tidur pada mahasiswa prodi DIII Keperawatan Politeknik Kaltara","authors":"Sriargianti Amir, Nining Nining","doi":"10.57174/jborn.v2i3.56","DOIUrl":"https://doi.org/10.57174/jborn.v2i3.56","url":null,"abstract":"Tidur merupakan suatu kegiatan normal yang akan dialami setiap individu dan menjadi aktivitas manusiawi namun banyak mahasiswa yang tidak memedulikan kualitas tidur yang baik, sehingga mempengaruhi tingkat kebugaran dan akan akan berdampak buruk bagi tubuh. Oleh karena itu, dengan memberikan senam yoga diharapkan menjadi salah satu cara dalam meningkatkan kualitas tidur pada berbagai umur dan penderita ganguan kualitas tidur. Tujuan penelitian ini untuk identifikasi efektifitas yoga terhadap peningkatan kualitas tidur pada mahasiswa. Metode penelitian ini menggunakan desain quasi experimental without control groub yang diberikan pre-test dan post-test. Populasi dalam penelitian adalah semua mahasiswa Prodi keperawatan Politeknik Kaltara dengan jumlah populasi 131 populasi dengan teknik pengambilan sampel menggunakan purposive sampling pada mahasiswa keperawatan tingkat 1 dengan jumlah sampel 33 sampel. Tahapan penelitian terdiri dari 3 tahapan. Analisa data yang digunakan adalah analisis univariat dan bivariat. Hasil uji analisis menggunakan McNemar dan didapatkan ρ-value = 0.000 (< 0,05) yang berarti terdapat perbedaan signifikan terhadap kualitas tidur sebelum dan sesudah intervensi senam yoga. Kesimpulan dari penelitian ini adalah senam yoga dapat meningkatkan kualitas tidur pada mahasiswa Keperawatan di Politeknik Kaltara.","PeriodicalId":9118,"journal":{"name":"Borneo Journal of Pharmacy","volume":"106 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88019756","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sari Wijayanti, Heriani Heriani, Faizal Mustamin, Syuhada Syuhada
Salah satu tumbuhan obat yang ada di Indonesia adalah rambusa (Passiflora foetida L.). Beberapa zat kimia yang terkandung di dalam daun rambusa antara lain alkaloid, flavonoid, steroid dan triterpenoid yang mempunyai efek sebagai antibakteri. Penelitian ini bertujuan untuk mengetahui aktivitas dan konsentrasi antibakteri yang efektif dari ekstrak daun rambusa terhadap pertumbuhan bakteri Pseudomonas aeruginosa. Uji antibakteri dilakukan dengan menggunakan disc diffusion atau metode Kirby dengan konsentrasi uji 10%, 15%, 20%, dan kontrol positif (Ciprofloxacin). Hasil penelitian menunjukkan daya hambat antibakteri ekstrak daun rambusa konsentrasi 10%, 15%, 20%, dan kontrol positif secara berurutan adalah 2,63 mm, 4,53 mm, 6,05 mm, dan 26,72. Konsentrasi 20% ekstrak daun rambusa menunjukkan aktivitas antibakteri sedang dengan diameter zona hambat yaitu 6,05 mm.
{"title":"Ujı aktıvıtas antıbakterı ekstrak etanol daun rambusa (Passiflora foetida L.) terhadap bakterı Pseudomonas aeruginosa","authors":"Sari Wijayanti, Heriani Heriani, Faizal Mustamin, Syuhada Syuhada","doi":"10.57174/jborn.v2i3.61","DOIUrl":"https://doi.org/10.57174/jborn.v2i3.61","url":null,"abstract":"Salah satu tumbuhan obat yang ada di Indonesia adalah rambusa (Passiflora foetida L.). Beberapa zat kimia yang terkandung di dalam daun rambusa antara lain alkaloid, flavonoid, steroid dan triterpenoid yang mempunyai efek sebagai antibakteri. Penelitian ini bertujuan untuk mengetahui aktivitas dan konsentrasi antibakteri yang efektif dari ekstrak daun rambusa terhadap pertumbuhan bakteri Pseudomonas aeruginosa. Uji antibakteri dilakukan dengan menggunakan disc diffusion atau metode Kirby dengan konsentrasi uji 10%, 15%, 20%, dan kontrol positif (Ciprofloxacin). Hasil penelitian menunjukkan daya hambat antibakteri ekstrak daun rambusa konsentrasi 10%, 15%, 20%, dan kontrol positif secara berurutan adalah 2,63 mm, 4,53 mm, 6,05 mm, dan 26,72. Konsentrasi 20% ekstrak daun rambusa menunjukkan aktivitas antibakteri sedang dengan diameter zona hambat yaitu 6,05 mm.","PeriodicalId":9118,"journal":{"name":"Borneo Journal of Pharmacy","volume":"20 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77841232","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：